267 related articles for article (PubMed ID: 20371442)
21. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
22. Romidepsin for cutaneous T-cell lymphoma.
Prince HM; Dickinson M; Khot A
Future Oncol; 2013 Dec; 9(12):1819-27. PubMed ID: 24295412
[TBL] [Abstract][Full Text] [Related]
23. Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
Belvedere S; Witter DJ; Yan J; Secrist JP; Richon V; Miller TA
Bioorg Med Chem Lett; 2007 Jul; 17(14):3969-71. PubMed ID: 17507219
[TBL] [Abstract][Full Text] [Related]
24. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
[No Abstract] [Full Text] [Related]
25. Vorinostat.
Grant S; Easley C; Kirkpatrick P
Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
[No Abstract] [Full Text] [Related]
26. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
27. Romidepsin for the treatment of cutaneous T-cell lymphoma.
Campas-Moya C
Drugs Today (Barc); 2009 Nov; 45(11):787-95. PubMed ID: 20126671
[TBL] [Abstract][Full Text] [Related]
28. Romidepsin for cutaneous T-cell lymphoma.
Prince HM; Dickinson M
Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
[TBL] [Abstract][Full Text] [Related]
29. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; He K; Sridhara R; Abraham S; Booth BP; Verbois L; Morse DE; Jee JM; Pope S; Harapanhalli RS; Dagher R; Farrell A; Justice R; Pazdur R
Clin Cancer Res; 2007 Apr; 13(8):2318-22. PubMed ID: 17438089
[TBL] [Abstract][Full Text] [Related]
30. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
Zirlik K; Nashan D; Veelken H
Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
[No Abstract] [Full Text] [Related]
31. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
Jain N; Odenike O
Expert Opin Pharmacother; 2010 Dec; 11(18):3073-84. PubMed ID: 21080855
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
Slingerland M; Guchelaar HJ; Gelderblom H
Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
[TBL] [Abstract][Full Text] [Related]
33. The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
Horwitz SM
Curr Hematol Malig Rep; 2011 Mar; 6(1):67-72. PubMed ID: 21080243
[TBL] [Abstract][Full Text] [Related]
34. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Grant C; Rahman F; Piekarz R; Peer C; Frye R; Robey RW; Gardner ER; Figg WD; Bates SE
Expert Rev Anticancer Ther; 2010 Jul; 10(7):997-1008. PubMed ID: 20645688
[TBL] [Abstract][Full Text] [Related]
35. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
36. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
Duvic M; Vu J
Expert Opin Investig Drugs; 2007 Jul; 16(7):1111-20. PubMed ID: 17594194
[TBL] [Abstract][Full Text] [Related]
37. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.
Duvic M; Bates SE; Piekarz R; Eisch R; Kim YH; Lerner A; Robak T; Samtsov A; Becker JC; McCulloch W; Waksman J; Whittaker S
Leuk Lymphoma; 2018 Apr; 59(4):880-887. PubMed ID: 28853310
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
Sung JJ; Ververis K; Karagiannis TC
J Photochem Photobiol B; 2014 Feb; 131():104-12. PubMed ID: 24518645
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors in lymphoma and solid malignancies.
Rasheed W; Bishton M; Johnstone RW; Prince HM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):413-32. PubMed ID: 18366289
[TBL] [Abstract][Full Text] [Related]
40. HDAC inhibitor-based therapies and haematological malignancy.
Stimson L; Wood V; Khan O; Fotheringham S; La Thangue NB
Ann Oncol; 2009 Aug; 20(8):1293-302. PubMed ID: 19515748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]